The best indicator for Johnson & Johnson (JNJ)
We backtested 20 indicators across daily, weekly and hourly charts on real Johnson & Johnson (JNJ) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
EMA 20/50 Cross
On the weekly chart, this is the strongest risk-adjusted edge we found for Johnson & Johnson (JNJ) over ~64.7 years — trailing buy-and-hold by 4.1% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | EMA 20/50 Cross ✓ | Weekly | 9.6% | 0.58 | -60.3% | 46.7% | 30 | -4.1% |
| 2 | RSI Trend (>50) ✓ | Weekly | 8.6% | 0.56 | -45.3% | 43.5% | 170 | -5.1% |
| 3 | EMA 50/200 Cross ✓ | Daily | 8.8% | 0.54 | -59.5% | 34.0% | 50 | -4.9% |
| 4 | SMA 50/200 Cross ✓ | Daily | 8.1% | 0.51 | -70.2% | 43.5% | 46 | -5.6% |
| 5 | Rate of Change ✓ | Weekly | 7.1% | 0.49 | -41.6% | 45.7% | 210 | -6.6% |
| 6 | RSI Trend (>50) ✓ | Daily | 6.5% | 0.47 | -54.0% | 37.1% | 873 | -7.2% |
| 7 | WaveTrend (8/6/4) ✓ | Daily | 6.4% | 0.47 | -36.5% | 68.8% | 234 | -7.3% |
| 8 | CCI ✓ | Weekly | 4.3% | 0.46 | -38.0% | 83.9% | 56 | -9.4% |
| 9 | EMA-10 Trend ✓ | Weekly | 6.2% | 0.46 | -41.5% | 46.6% | 309 | -7.5% |
| 10 | Donchian Midline ✓ | Weekly | 6.6% | 0.46 | -45.0% | 48.0% | 179 | -7.2% |
| 11 | WaveTrend (8/6/4) ✓ | Weekly | 4.9% | 0.45 | -38.0% | 83.7% | 49 | -8.8% |
| 12 | Williams %R ✓ | Daily | 5.5% | 0.44 | -40.7% | 72.4% | 421 | -8.2% |
| 13 | CCI ✓ | Daily | 5.5% | 0.44 | -40.6% | 73.8% | 298 | -8.2% |
| 14 | EMA 20/50 Cross ✓ | Daily | 6.1% | 0.43 | -42.1% | 41.6% | 154 | -7.6% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Johnson & Johnson (JNJ), EMA 20/50 Cross on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.